Abstract: Provided are compounds, pharmaceutical compositions containing such compounds and methods for using the compounds the treatment or prevention of autoimmune diseases and disorders associated with antigen presentation by MHC Class II HLA-DRB1*15:O1 and furthermore, have improved metabolic stability compared to previous inhibitors.

Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.

Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.

Abstract: Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.

Abstract: Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.

Abstract: Melanocortin receptor-specific compounds of formula I below: wherein the variables are as defined in the specification, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders.

Abstract: Provided herein are novel compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds described herein are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

Abstract: Melanocortin receptor-specific compounds of formula I below: wherein the variables are as defined in the specification, and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. Compounds disclosed herein bind to one or more melanocortin receptors and may be an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist as to one or more melanocortin receptors, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders.

Abstract: A cleaning wipe including a fiber web and a tacky material. The fiber web defines opposing surfaces and an intermediate region between the opposing surfaces. In this regard, at least one of the opposing surfaces serves as a working surface for the cleaning wipe. The tacky material is applied to the web such that a level of tacky material is greater in the intermediate region than at the working surface. In one embodiment, the amount of tacky material per area of web material is greater in the intermediate region than at either of the opposing surfaces. In another embodiment, the fiber web is a nonwoven fiber web.

Abstract: The present invention features a fabric useful for applying a chemical composition, such as a finishing or polishing composition, onto a substrate surface. Typically the fabric contains between about 1% and 50% stiff fibers and between about 50% and 99% adsorbent or absorbent fibers, more typically between about 2% and 10% stiff fibers and between about 90% and 98% adsorbent or absorbent fibers. The fabric can be used to make applicator pads useful, for example, as mop heads for spreading a finishing or polishing composition on a floor surface.

Abstract: A cleaning wipe including a fiber web and a tacky material. The fiber web defines opposing surfaces and an intermediate region between the opposing surfaces. In this regard, at least one of the opposing surfaces serves as a working surface for the cleaning wipe. The tacky material is applied to the web such that a level of tacky material is greater in the intermediate region than at the working surface. In one embodiment, the amount of tacky material per area of web material is greater in the intermediate region than at either of the opposing surfaces. In another embodiment, the fiber web is a nonwoven fiber web.

Abstract: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.

Abstract: A dosing device is described, in which a predetermined amount of a material such as a concentrated fluid can be dispensed from the device by finger pressure. In one embodiment, the device includes a shuttle that can move between first and second positions. In the second position, fluid can escape from a dosing chamber.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: The present invention provides methods of treating a lymphoma (e.g.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: A mop assembly including a mop head and handle, and a supply of liquid connected to a valve assembly on the handle. The valve assembly includes a replaceable length of resiliently flexible tubing having a portion extending transversely through the handle and members on opposite sides of the length of tubing that are relatively movable between a closed position pinching together opposite sides of the tubing to stop the flow of liquid through it, and a spaced open position affording flow of liquid through the tube. A storage cart includes a main portion and a tray portion having a receptacle for receiving the mop head mounted on the main portion for relative movement between a vertical closed position at which the main portion covers an open side of the receptacle; and a horizontal open position at which the mop head can be inserted into or removed from the receptacle.

Abstract: The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.

Abstract: The present invention provides methods of treating, parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.